Secondary prevention of myocardial infarction: Beneficial effect of combining oral anticoagulant plus aspirin: Therapy based on evidence

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 3, 2000, Pages 126-134

  Altman, R ^a   Rouvier, J ^a   Scazziota, A ^a  

^a Centro de Trombosis de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; HEART INFARCTION PREVENTION; HEART REINFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS;

EID: 0033836772     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600302     Document Type: Review

References (73)

1. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
2. Angioscopic coronary macromorphology in patients with acute coronary disorders
3. Atherosclerosis. An inflammatory disease
4. Regulation of the thrombotic potential of atheroma
5. Histological patterns of atherosclerotic plaques in unstable angina patients vary according to clinical presentation
6. Coronary plaque erosion without rupture into a lipid core
7. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from stable to the unstable clinical state
8. Molecular bases of the acute coronary syndromes
9. Mechanisms of progression in native coronary artery disease: Role of healed plaque disruption
10. Atherothrombosis: The role of platelets
11. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
12. Macrophages, smooth muscle cells, and tissue factor in unstable angina
13. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions
14. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets
15. The unstable atherosclerotic plaque: Clinical significance and therapeutic intervention
16. Mechanism of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow at the apex of stenotic severely injured vessel wall. Experimental studies in the pig model
17. Importance of thrombosis and thrombolysis in silent ischemia: Comparison of patients with acute myocardial infarction and unstable angina
18. Endothelial disfunction, hemodynamic forces, and atherosclerosis
19. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes
20. Monocyte/macrophage regulation of coagulant events
21. Histidine phosphorylation of P-selectin upon ligand-induced stimulation of human platelets: A novel pathway for cell activation dependent signal transduction
22. Leukocyte crosstalk at the vascular wall
23. Fluid shear stress modulates von Willebrand factor release from human vascular endothelium
24. Platelets and atherosclerosis
25. Platelet and fibrin deposition at the damaged vessel wall: Cooperative substrates for neutrophil adhesion under flow conditions
26. Morphology of occlusive coronary thrombi. Localization, length, composition, growth
27. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Natural history and the effect of thrombolysis
28. Aspirin as an antiplatelet drug
29. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: Executive summary and recommendations
30. On Behalf of the Societies. Joint British recommendations on prevention of coronary heart disease in clinical practice
31. Antithrombotic agents in coronary artery disease
32. The use of aspirin in ischemic heart disease
33. A randomized controlled trial of aspirin in person recovered from myocardial infarction
34. Antithrombotic therapy in the secondary prevention of myocardial infarction
35. Anti-platelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy
36. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction
37. Marked reduction in long-term cardiac deaths with aspirin after a coronary event
38. Fracaso antiinflamatorio, antitrombotico o sesgo clinico? Aspirina previa y evolucion en la angina inestable: Estudio fisiopatologico
39. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and increased risk
40. Angina pectoris and disease progression
41. Aspirin as a therapeutic agent in cardiovascular association
42. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant
43. Aspirin and platelets
44. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
45. Cumulative antiplatelet effect of low-dose enteric coated aspirin
46. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
47. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
48. Prevention of myocardial infarction and stroke by aspirin: Different mechanisms? Different dosage?
49. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction
50. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction
51. The effect of warfarin on mortality and re-infarction after myocardial infarction
52. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
53. Optimal intensity of oral anticoagulant therapy after myocardial infarction
54. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation
55. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction
56. SPAF-III results
57. Oral anticoagulant treatment with and without aspirin
58. Secondary prevention of myocardial infarction: A comparison between acetylsalicylic acid, placebo and phenprocoumon
59. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction
60. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): A multicenter unblinded randomised clinical trial
61. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
62. Hemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
63. Effect of treatment with low-dose warfarin-aspirin on activated factor XII
64. Oral anticoagulants in patients with mechanical cardiac valves replacement. The role of aspirin
65. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users
66. Progression of the culprit lesion in unstable coronary disease with warfarin and aspirin versus aspirin alone: Preliminary study
67. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to assess strategies for ischemic syndromes (OASES) pilot study results
68. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: A study in 3166 outpatients
69. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical prosthetic heart valves
70. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
71. Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies
72. Antithrombotic treatment following acute ischemic heart disease: Acetylsalicylic acid and (or) oral anticoagulants? ASPECT-II, a new study